IN8bio’s DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer
Preclinical results showcase the potential for the strong synergistic combination of chemotherapy and gamma-delta T cell therapy to target solid...
Preclinical results showcase the potential for the strong synergistic combination of chemotherapy and gamma-delta T cell therapy to target solid...
In study conducted for U.S. Army Medical Research Institute, SAB-183 demonstrated strong immune protection and response against Yersinia pestis infection,...
OXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage...
In the first quarter of 2023, Mendus continued on the path set out by the key progress realized at the...
– Continued to enroll patients in VIRAGE, the Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy...
Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call Begins...
NEEDHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage...
- FDA has approved five of seven sections in a rolling submission required for a New Animal Drug Application (NADA)...
Media Release SYDNEY, AUSTRALIA, May 09, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),...
NEW YORK, May 09, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and...
The T-Cell Therapy product candidate contains a neoantigen-specific T-cell receptor (TCR) identified and characterized through Adaptive’s TCR discovery platformSEATTLE, May...
New Drug Application for YCANTH™ (VP-102) PDUFA Goal Date of July 23, 2023 - Potential to Become Only FDA-approved Therapy...
- Investigational New Drug (IND) application for SNS-101 cleared by U.S. Food and Drug Administration (FDA) with first patient dose...
SAN DIEGO and SUZHOU, China, May 04, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology...
Eterna to present data on iPS cell-derived multi-cell-type therapeutic strategy for solid-tumor targeting, nucleic-acid delivery, and targeted gene insertion CAMBRIDGE,...
LAWRENCEVILLE, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated...
First fully-human multi-epitope binding broadly neutralizing immunoglobulin antibody therapeutic being developed for treatment of high-risk patients demonstrates safety and efficacy...
FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a...
Q1 2023 total revenues of $95.3 million, compared to $35.0 million in the same period in 2022 CAPLYTA Q1 2023...
Dr. Newman also to give two presentations on the Company’s Decoy platform at the event to be held in Boston...